Researchers at the University of Oxford reported that a specialized human microglia population shields dopamine neurons in Parkinson’s disease by selectively removing alpha-synuclein aggregates through GPNMB-mediated trogocytosis. The finding links an immune-effector mechanism to neuronal vulnerability and provides mechanistic detail beyond descriptive neuroinflammation. The work positions GPNMB-mediated microglial aggregate clearance as a potential therapeutic direction, especially for strategies that aim to reduce toxic intracellular alpha-synuclein burden. As a human-focused mechanistic result, it supports deeper target validation and may inform both biomarker development and future immunomodulatory intervention design.